Imatinib Grindeks (Imatinib)

Imatinib binds competitively to the ATP‑binding pocket of the BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. This blocks phosphorylation of downstream substrates, halting the signaling cascades that promote proliferation and survival of cancer cells. By disabling these oncogenic pathways, the drug induces apoptosis or growth arrest in cells that depend on the inhibited kinases.

The dose of Imatinib Grindeks is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and any concomitant medications. Clinicians follow established treatment guidelines and may adjust the regimen according to therapeutic response and tolerability, so patients should never modify the dose without medical advice.

The safety of Imatinib during pregnancy and lactation has not been established; it is classified as pregnancy category unknown. Because the drug can cross the placenta and is excreted in breast milk, it is generally avoided unless the potential benefit justifies the risk. Women of child‑bearing potential should discuss contraception and treatment options with their healthcare provider.

To request Imatinib Grindeks, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required temperature controls) and assistance with import documentation.

Imatinib was the first approved BCR‑ABL tyrosine‑kinase inhibitor and remains a standard first‑line option for chronic‑phase CML. Newer agents such as dasatinib and nilotinib offer alternative potency and activity against some resistant mutations, but they may have different safety profiles. Choice of therapy depends on mutation status, patient comorbidities, and physician assessment of risk‑benefit balance.

Imatinib Grindeks tablets should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the product in its original blister or bottle, protect it from moisture, excessive heat and direct sunlight. Do not refrigerate or freeze the tablets, and ensure the packaging remains sealed until use.

Imatinib Grindeks is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed. Patients should follow the dosing schedule provided by their oncologist and attend regular monitoring appointments.

The most serious adverse events include hepatotoxicity, severe neutropenia or thrombocytopenia, cardiotoxicity (such as reduced left‑ventricular ejection fraction), and rare anaphylactic reactions. Early detection through routine laboratory tests and clinical assessment is essential. Patients should report signs of liver dysfunction, unexplained bleeding, shortness of breath, or allergic symptoms promptly.

Imatinib Grindeks is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. Caution is advised for individuals with pre‑existing severe hepatic impairment, uncontrolled cardiac disease, or those receiving strong CYP3A4 inducers or inhibitors without appropriate dose adjustments. Pregnant or nursing women should avoid use unless the therapeutic benefit outweighs potential risks.